



Department of Consumer & Business Services

Insurance Division — 2

P.O. Box 14480

Salem, Oregon 97309-0405

Phone: (503) 947-7269

Fax: (503) 378-4351

350 Winter St. NE, Rm. 440, Salem, Oregon

www.oregoninsurance.org

External Review Annual Summary

External Review Annual Summary for 20 08 .

Due on March 31 for previous calendar year.

Each independent review organization (IRO) shall submit an annual statistical report with information in the aggregate on its Oregon Insurance Division external reviews only. OARs 836-053-1350(1), 836-053-1360(2)

- 1. IRO name: Permedion Filing date: 02/06/2009
2. IRO address: 350 Worthington Rd., Suite H City, state, ZIP: Westerville, Ohio 43082
3. IRO Web site: www.permedion.com
4. Name, e-mail address, phone and fax number for person completing this form: Sue Butterfield sbutterfield@permedion.com 614-839-3428 Fax: 614-839-2628
5. Name and title of person responsible for regulatory compliance and quality of external reviews: Tom Schultz President Name: David Sand MD Title: Medical Director
6. Total number of requests for external review received from the Oregon Insurance Division during the reporting period: 17
7. Number of standard OID reviews completed to a final decision: 15
8. Average number of days IRO required to reach a final decision in standard reviews: 15.4
9. Number of expedited OID reviews completed to a final decision: 0
10. Average number of days IRO required to reach a final decision in expedited reviews: N/A
11. Number of medical-necessity reviews decided in favor of the insurer: 5 Genotropin-constitutional delay; Rozerem>14/mo-insomnia (sleep apnea); Lipitor vs generic meds-high cholesterol; Adult Growth Hormone Deficiency Briefly list procedures denied: (Genotropin); Tiered co-payment exception for OxyContin
12. Number of medical-necessity reviews decided in favor of the enrollee: 2 Briefly list procedures approved: Byetta for treatment of diabetes; Replax for treatment of migraine
13. Number of experimental/investigational reviews decided in favor of the insurer: 4



Briefly list procedures denied: Oncotype DX analysis; Continuous Glucose Monitor; Oncotype DX Analysis; Use of Alloderm in breast reconstruction

14. Number of experimental/investigational reviews decided in favor of the enrollee: 4

Briefly list procedures approved: Oncotype DX analysis; Oncotype DX Analysis; Oncotype DX Analysis; Use of ProDisc

15. Number of continuity-of-care reviews decided in favor of the insurer: N/A Enrollee: N/A

16. Number of OID review requests for which the IRO deemed it did not have jurisdiction under ORS 743.857: 0

17. Number of OID reviews terminated as the result of reconsideration by the insurer: 0

18. Number of OID reviews terminated by the enrollee: 0

19. Number of reviews declined due to possible conflict of interest with insurer: 0 Enrollee: 0

Describe possible conflict(s) of interest: N/A

20. Number of enrollees who complained to the IRO at least once about their external review: 0